A Supreme Court decision in June to strike down a company's
patent on genes linked to breast cancer could have far - reaching consequences for biotechnology and medical research.
Not exact matches
Myriad's portfolio also includes
patents on methods of analyzing BRCA
genes for
links to cancer — and these are outside the scope of the current case.
That question will be debated once more
on 20 July when Myriad Genetics, a diagnostic company in Salt Lake City, Utah, returns to the US courts to argue that its
patents on the BRCA1 and BRCA2
gene variants —
linked to inherited breast and ovarian cancer — are valid.